Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex has reported strong financial results for Q2 2021, achieving revenues of $713.5 million, a 25.8% year-over-year increase. GAAP diluted EPS surged to $1.76 from $0.24 in the prior period, while adjusted diluted EPS rose 73.6% to $3.35. The company's 2021 guidance remains unchanged, with revenue growth projected between 10.50% and 11.75%. Despite a $28-$32 million revenue headwind expected from its recent respiratory divestiture, the company maintains a positive outlook for its Interventional Urology business, anticipating over 30% growth.
Teleflex (NYSE: TFX) announced a conference call scheduled for July 29, 2021, at 8:00 a.m. ET to discuss its second-quarter financial results and provide an operational update. The call will be accessible via a live audio webcast on teleflex.com. An audio replay will be available later that day, with dial-in options provided for listeners. Teleflex is a global leader in medical technologies, focusing on enhancing patient health and healthcare delivery through innovative solutions.
Teleflex has revealed that the UroLift System yields the lowest overall complication rates among BPH treatments, based on the largest U.S. healthcare claims study presented at the European Association of Urology Congress. An analysis of over 33,000 claims showed a complication rate of 16.3% for the UroLift System at 300 days post-treatment, compared to 19.7% for TURP and 21.6% for GreenLight. The research emphasizes the UroLift System's durability with a low retreatment rate of 6.8% at 1,500 days, comparable to TURP. This data sets a new standard for evaluating minimally invasive BPH procedures.
Teleflex announced presentations at the 36th European Association of Urology Congress highlighting new data on the UroLift System for treating benign prostatic hyperplasia (BPH). Scheduled from July 8-12, these presentations will showcase real-world effectiveness and durability results, emphasizing Real-World Data to complement randomized controlled trials. The UroLift is minimally invasive, preserving sexual function, and has treated over 250,000 men globally. The studies aim to improve understanding of patient outcomes and advance treatment protocols.
Teleflex (NYSE:TFX) announced the completion of the divestiture of a significant portion of its respiratory business to Medline for $286 million, reducing to $274 million due to working capital adjustments. The divested product lines, generating $139 million in 2020, are projected to contribute flat net revenue in 2021. This move is estimated to create a $28-$32 million revenue headwind and a $0.10-$0.15 EPS dilution, approximately 1% of adjusted EPS for 2021. Proceeds will be used to pay down debt, enhancing financial flexibility.
Teleflex has released a survey indicating that men with urinary symptoms due to benign prostatic hyperplasia (BPH) often engage in extreme bathroom planning, impacting their daily activities. Conducted with 1,000 U.S. men aged 45+, the study found that 45.49% avoided enjoyable events due to urinary issues. Over 70% reported diminished energy levels from nighttime awakenings. While many men (66.81%) are interested in minimally invasive procedures, nearly 25% find current BPH medications ineffective. The UroLift System offers a promising alternative for symptom relief.
Teleflex's Executive Vice President and CFO, Thomas Powell, will present at the Raymond James 2021 Human Health Innovation Conference on June 21, 2021, at 8:40 a.m. (ET). A live audio webcast and slide presentation will be available on the Teleflex website.
Teleflex offers a range of medical technologies aimed at improving health and quality of life. Their innovative solutions cover areas such as vascular access, interventional cardiology, anesthesia, and more. The company, listed on the NYSE as TFX, is dedicated to addressing unmet clinical needs.
Teleflex has announced a definitive agreement to sell a significant portion of its Respiratory business to Medline Industries for $286 million, minus $12 million in working capital. The divested product lines generated $139 million in revenue in 2020, with flat growth expected in 2021. The transaction, anticipated to close in early Q3 2021, will incur a revenue headwind of $28-32 million and dilute adjusted earnings per share by $0.10-$0.15. Teleflex plans to use the proceeds to reduce debt and focus on core market segments.
Thomas Powell, Executive Vice President and CFO of Teleflex (NYSE: TFX), will present at the UBS Global Healthcare Virtual Conference on May 25, 2021, at 3:00 p.m. (ET). The event will include a live audio webcast and a slide presentation available on the investor section of the Teleflex website. Teleflex is known for its innovative medical technologies aimed at improving health outcomes across various fields, including vascular access and emergency medicine. The company emphasizes its commitment to addressing unmet clinical needs through its diverse product portfolio.
Teleflex Incorporated (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share, payable on June 15, 2021, to shareholders of record as of May 14, 2021. This decision reflects the company's commitment to returning value to its shareholders while continuing to focus on improving healthcare through innovative medical technologies across various fields including vascular access and anesthesia. Teleflex maintains a diverse portfolio aimed at meeting unmet clinical needs.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
